Bronwyn A L Crawford,* Channa Perera†
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 Royal Prince Alfred Hospital and the University of Sydney, Sydney, NSW 2050
- 2 Orange Base Hospital, Orange.
Correspondence: brcrawfo@mail.usyd.edu.au
- 1. Veitch PC, Clifton-Bligh RJ. Long-acting sulfonylureas — long acting hypoglycaemia. Med J Aust 2004; 180: 84-85. <eMJA full text>
- 2. Boyle PJ, Justice K, Krentz AJ, et al. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 1993; 76: 752-756.
- 3. Braatvedt GD. Octreotide for the treatment of sulfonylurea-induced hypoglycaemia in type 2 diabetes. N Z Med J 1997; 110: 189-190.
- 4. Graudins A, Linden CH, Ferm RP. Diagnosis and treatment of sulfonylurea-induced hyperinsulinemia hypoglycemia. Am J Emerg Med 1997; 15: 95-96.
- 5. Krentz AJ, Boyle PJ, Justice KM, et al. Successful treatment of severe refractory sulfonylurea-induced hypoglycemia with octreotide. Diabetes Care 1993; 16: 184-186.
Online responses are no longer available. Please refer to our instructions for authors page for more information.